AR061887A1 - Una composicion de vacuna contra el dengue - Google Patents

Una composicion de vacuna contra el dengue

Info

Publication number
AR061887A1
AR061887A1 ARP070103083A ARP070103083A AR061887A1 AR 061887 A1 AR061887 A1 AR 061887A1 AR P070103083 A ARP070103083 A AR P070103083A AR P070103083 A ARP070103083 A AR P070103083A AR 061887 A1 AR061887 A1 AR 061887A1
Authority
AR
Argentina
Prior art keywords
vaccine
composition
serotype
dose
dengue virus
Prior art date
Application number
ARP070103083A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR061887A1 publication Critical patent/AR061887A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Una composicion de vacuna que comprende (i) una dosis de un virus del dengue vacunal de un primer serotipo y una dosis de un virus del dengue vacunal de un segundo serotipo y (ii) una dosis de un virus del dengue vacunal de un tercer serotipo y una dosis de un virus del dengue vacunal de un cuarto serotipo, como composicion de vacuna de combinacion contra el dengue para la administracion sucesiva, en la cual los virus del dengue vacunales (ii) se administran por lo menos 30 días y a lo sumo 1 ano después de la administracion de lo virus del dengue vacunal (i).
ARP070103083A 2006-07-12 2007-07-11 Una composicion de vacuna contra el dengue AR061887A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0606324A FR2903605A1 (fr) 2006-07-12 2006-07-12 Methode d'immunisation contre les quatres serotypes de la dengue

Publications (1)

Publication Number Publication Date
AR061887A1 true AR061887A1 (es) 2008-10-01

Family

ID=37866217

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103083A AR061887A1 (es) 2006-07-12 2007-07-11 Una composicion de vacuna contra el dengue

Country Status (16)

Country Link
US (2) US7718357B2 (es)
EP (1) EP2043680A1 (es)
JP (1) JP5295956B2 (es)
KR (1) KR20090027759A (es)
CN (1) CN101489585B (es)
AR (1) AR061887A1 (es)
AU (1) AU2007274100B2 (es)
BR (1) BRPI0712878A2 (es)
CA (1) CA2656349A1 (es)
FR (1) FR2903605A1 (es)
IL (1) IL196331A0 (es)
MX (1) MX2009000369A (es)
MY (1) MY169275A (es)
TW (1) TWI400333B (es)
WO (1) WO2008007021A1 (es)
ZA (1) ZA200900155B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
EP2632485A4 (en) 2010-10-29 2014-05-28 Merck Sharp & Dohme RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS
CN104812408A (zh) 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
MY168959A (en) * 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
AU2018346724A1 (en) 2017-10-05 2020-05-14 Sanofi Pasteur Compositions for booster vaccination against dengu
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
JP2022544613A (ja) 2019-08-16 2022-10-19 タケダ ワクチン，インコーポレイテッド デング熱及びａ型肝炎を予防するための方法
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061916A1 (en) 1998-05-29 1999-12-02 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
KR100721745B1 (ko) * 1999-03-26 2007-05-25 왈터 리드 아미 인스티튜트 오브 리써치 다가 뎅기 바이러스 백신
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
PT2278012E (pt) 2000-02-16 2015-11-30 Univ Mahidol Quimeras imunogénicas do vírus do dengue 2
PT1159968E (pt) 2000-05-30 2008-11-20 Univ Mahidol Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CN1234852C (zh) * 2003-01-30 2006-01-04 上海天甲生物医药有限公司 一种以登革热病毒重组复制子为载体的假病毒颗粒疫苗
MXPA05010255A (es) * 2003-03-24 2005-12-14 Scripps Research Inst Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas.
WO2006134443A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
WO2007021672A2 (en) * 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
MY169275A (en) 2019-03-21
JP5295956B2 (ja) 2013-09-18
AU2007274100A1 (en) 2008-01-17
AU2007274100B2 (en) 2013-02-07
KR20090027759A (ko) 2009-03-17
BRPI0712878A2 (pt) 2012-09-04
WO2008007021A1 (fr) 2008-01-17
TWI400333B (zh) 2013-07-01
US20080014219A1 (en) 2008-01-17
TW200813228A (en) 2008-03-16
CA2656349A1 (en) 2008-01-17
MX2009000369A (es) 2009-01-29
EP2043680A1 (fr) 2009-04-08
ZA200900155B (en) 2010-03-31
FR2903605A1 (fr) 2008-01-18
CN101489585A (zh) 2009-07-22
IL196331A0 (en) 2011-08-01
US20100221285A1 (en) 2010-09-02
CN101489585B (zh) 2013-12-04
US7718357B2 (en) 2010-05-18
JP2009542783A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
AR061887A1 (es) Una composicion de vacuna contra el dengue
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
AR063057A1 (es) Metodo de inmunizacion contra los 4 serotipos de dengue
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
CY1118017T1 (el) Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
ECSP10010002A (es) Derivados indólicos 2,3 sustituidos y métodos de uso de los mismos
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
ECSP088208A (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CO6190623A2 (es) Vacuna salmonella
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CL2011003043A1 (es) Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue.
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
BRPI0917502A2 (pt) composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral

Legal Events

Date Code Title Description
FA Abandonment or withdrawal